RxDoctor Payments Data

Harmeet Malhi

Gastroenterology · Rochester, MNNPI 1275507600

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Merck accounts for 79.9% of it on its own, with 1 other manufacturer making up the rest.

$22,253in general payments, 2019–2025

Across 26 payments — averaging $855.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$18K
  • Pfizer$4K
$118,704in research payments, 2019–2025

Across 13 payments — averaging $9131.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$79K
  • Pfizer$40K

What the payments were for

  • Consulting fees$12,81058%
  • Speaking & faculty fees$4,48020%
  • Travel & lodging$4,29119%
  • Food & beverage$6723%

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck24$17,773
Pfizer2$4,480

How this compares

$22,253 in reported general payments places this provider in the 85th percentile of 365 gastroenterology providers in Minnesota.

See all gastroenterology providers in Minnesota

Medicare billing

Part B allowed, 2024
$8,164
Medicare patients
54
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$39,486
Spironolactone13$142
Carvedilol15$23

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →